Pamufetinib mesylate NEW
| Price | $93 | $155 | $586 |
| Package | 2mg | 5mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-13 |
Product Details
| Product Name: Pamufetinib mesylate | CAS No.: 1688673-09-7 |
| Purity: 98.91% | Supply Ability: 10g |
| Release date: 2025/06/13 |
Product Introduction
Bioactivity
| Name | Pamufetinib mesylate |
| Description | Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases. |
| In vitro | Pamufetinib mesylate is an ATP antagonist with inhibition constants (Ki) of 12 nM and 39 nM for rVEGFR2 and rMET, respectively.It potently inhibits the kinase activity of VEGFR2 and MET and their signaling-dependent cellular growth, with effects comparable to other known VEGFR or MET inhibitors. In addition, Pamufetinib mesylate caused less damage to a variety of normal cells than other VEGFR inhibitors. At concentrations below 10 μM, Pamufetinib mesylate did not affect the growth of PC-9 or HCC827 cells, but was able to concentration-dependently reverse HGF-induced resistance in both cell lines when combined with erlotinib. In addition, Pamufetinib mesylate inhibits VEGF production and endothelial cell proliferation in cancer cells. [1][2] |
| In vivo | Pamufetinib mesylate (50 mg/kg/d) was able to completely inhibit tumor growth during treatment. And in a MET-amplified human cancer transplant model, Pamufetinib mesylate (200 mg/kg/d) regressed tumor volume by 48% from the initial volume. In this model, the 50% effective dose (ED50) of Pamufetinib was estimated to be 8 mg/kg/d. Pamufetinib mesylate significantly prolonged survival in mice when administered at doses of 50 or 200 mg/kg/d. Meanwhile, Pamufetinib mesylate effectively inhibited angiogenesis in the PC-9/HGF tumor model. In addition, the combination of erlotinib and Pamufetinib mesylate successfully inhibited PC-9/HGF tumor growth and delayed tumor regeneration that was still associated with persistent vasculature inhibition even after cessation of treatment. [1][2] |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | store at -20°C | Shipping with blue ice. |
| Solubility Information | DMSO : 60.00 mg/mL (97.61 mM), Sonication is recommended. |
| Keywords | VEGFR | TAS 115 Mesylate | rVEGFR2 | rMET | HGFR | c-Met/HGFR | cMet/HGFR | c-Met | cMet |
| Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Taxifolin | Sorafenib | L-Ascorbic acid 2-phosphate trisodium | Regorafenib | Sanguinarine chloride | Sorafenib tosylate | Lenvatinib mesylate | Pazopanib | Axitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $46.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-24 | |
| $46.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-15 | |
| $0.00/1g |
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-25 | |
| $155.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY